Knee OsteoarthritisSVFNCT06000670
Efficacy of Autologous Adipose Derived Stromal Vascular Fraction for Musculoskeletal Conditions
A study testing stromal vascular fraction injection in the osteoarthritic knee in people with Knee Osteoarthritis, run by Dubai Health Authority.
Trial summary
clinical efficacy of autologous stromal vascular fraction SVF,for inflammatory and degenerative conditions of the knees Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Knee Osteoarthritis
- What is being tested?
- stromal vascular fraction injection in the osteoarthritic knee
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- No sites listed yet
- Study dates
- 30 Dec 2026to 1 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- knee osteoarthritis any grade
- knee chondromalacia grade 2 and above
Who cannot join
- active HIV
- pregnant women
- Mental disease
- severe cardio vascular disease
- severe coagulation disorders
- infected tissues
- patients on other experimental studies within 3 months
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
clinical efficacy of autologous stromal vascular fraction SVF,for inflammatory and degenerative conditions of the knees
Read the detailed description
to evaluate the clinical effectiveness of point of care autologous adipose derived stromal vascular fraction (SVF) alone or in combination with exosomes,for inflammatory and degenerative conditions of the knees.
- Conditions
- Knee Osteoarthritis
- Being tested
- stromal vascular fraction injection in the osteoarthritic knee
- Keywords
- knee osteoarthritis, knee chondromalacia
- Medical subject headings
- Osteoarthritis, Knee
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
stromal vascular fraction injection in the osteoarthritic kneeProcedure or surgery
stromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee.
| Study group | Role | What they receive |
|---|---|---|
| knee osteoarhritis | Experimental | patients with grade 2 and above chondromlacia as well as all grades of osteoarhtritis Receives: Procedure: stromal vascular fraction injection in the osteoarthritic knee |
What is being measured
The primary outcome is the main question the study is designed to answer.
change in pain level
visual analog scale 0-10 ( 10 being worst)
Measured: 2 years
Secondary outcomes (1)
percentage cartilage thickness change
as measured by MRI
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Aug 2023
- Study start30 Dec 2026 (estimated)
- Primary completion30 Dec 2027 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Knee OsteoarthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Dubai Health Authority
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Amer Mansour, Dubai Health Authority
- Investigators
- DHA DHA, Study director, dubai health autority
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06000670
- Sponsor's protocol ID
- DHA
- Acronym
- SVF
- Status last verified
- Aug 2025
- First submitted
- 2 Aug 2023
- Last updated
- 26 Aug 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Autologous Adipose Derived Stromal Vascular Fraction for Musculoskeletal Conditions
- ClinicalTrials.gov ID
- NCT06000670
- Acronym / sponsor ID
- SVF / DHA
- Conditions
- Knee Osteoarthritis
- Keywords
- knee osteoarthritis, knee chondromalacia
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Dubai Health AuthorityOther government
- Study start
- 30 Dec 2026 (estimated)
- Primary completion
- 30 Dec 2027 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 21 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
clinical efficacy of autologous stromal vascular fraction SVF,for inflammatory and degenerative conditions of the knees
Detailed description
to evaluate the clinical effectiveness of point of care autologous adipose derived stromal vascular fraction (SVF) alone or in combination with exosomes,for inflammatory and degenerative conditions of the knees.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| knee osteoarhritis | Experimental | Procedure: stromal vascular fraction injection in the osteoarthritic kneepatients with grade 2 and above chondromlacia as well as all grades of osteoarhtritis |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- knee osteoarthritis any grade
Key exclusion criteria (7 listed)
- active HIV
- pregnant women
- Mental disease
- severe cardio vascular disease
- severe coagulation disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| stromal vascular fraction injection in the osteoarthritic kneestromal vascular fraction harvested from mid abdominal wall under sedation and seperated from fat using mechanical centrifugation .injection of 5 cc of the SVF in the affected knee. | Procedure or surgery | knee osteoarhritis |
Primary outcome
change in pain level
Time frame: 2 years
visual analog scale 0-10 ( 10 being worst)
1 secondary outcome
percentage cartilage thickness change
Time frame: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2025.
- cell surgical networkLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Knee Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
RecruitingObservational study
Exploring Factors Linked to Worsening Over Time in People With Early-stage Knee Osteoarthritis and Those With Prior Proven Acute Knee Injury.
Knee Osteoarthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
DHA DHA study director
dubai health autority
Questions about this trial
What is this clinical trial studying?
A study testing stromal vascular fraction injection in the osteoarthritic knee in people with Knee Osteoarthritis, run by Dubai Health Authority.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 26 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Amer Mansour, MD (+971502983375, dramermansour@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
change in pain level (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2025.